ReviewCancer imaging : the official publication of the International Cancer Imaging Society2026
Percutaneous ablation of T1b renal tumors: a review.
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgical excision is the gold standard treatment for T1b renal cell carcinoma (RCC). However, due to the comorbidities especially in elderly patients, not all are candidates for surgery or prefer surgical approaches. This has raised the interest in minimally invasive ablation therapy for such patient population given that ablation techniques have shown favorable long term oncologic and survival outcomes for T1 a renal tumor. This review article delves into the application of ablation technologies, including percutaneous cryoablation (PCA), radiofrequency ablation (RFA), and microwave ablation (MWA), for managing T1b renal tumors (4.1-7 cm). This review comprehensively explores patient selection, contraindications, clinical evaluation, ablation procedures, imaging modalities, technical considerations, complications, and follow-up care. Additional insights of the efficacy, safety, and outcomes of ablation techniques for treating T1b renal tumors are presented. As the field continues to evolve, understanding the nuances of ablation as an alternative treatment modality for T1b renal tumors becomes essential for optimizing patient care and decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.